Tema Etfs LLC Purchases 43,814 Shares of Genmab A/S Sponsored ADR $GMAB

Key Points

• Tema Etfs LLC increased its holdings in Genmab A/S by 74.3% during Q1, acquiring an additional 43,814 shares, bringing its total to 102,749 shares.
• Multiple institutional investors significantly boosted their stakes in Genmab A/S, with Headlands Technologies LLC increasing its holdings by 1,525.0% in the first quarter.
• Analysts have set a consensus price target of $37.60 for Genmab A/S, with most ratings leaning toward a "buy" despite a recent downgrade by Zacks.

Tema Etfs LLC increased its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 74.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,749 shares of the company's stock after purchasing an additional 43,814 shares during the quarter. Tema Etfs LLC's holdings in Genmab A/S were worth $2,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of GMAB. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after purchasing an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after purchasing an additional 1,070 shares in the last quarter. Barclays PLC lifted its holdings in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Genmab A/S during the fourth quarter valued at $60,000. Finally, Brooklyn Investment Group increased its position in Genmab A/S by 729.3% during the first quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock valued at $83,000 after acquiring an additional 3,734 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Zacks Research cut Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. Truist Financial upped their price objective on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Finally, HC Wainwright upped their price objective on Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and an average target price of $37.60.

Genmab A/S Stock Down 1.0%

GMAB traded down $0.24 during midday trading on Monday, reaching $24.87. The company had a trading volume of 676,680 shares, compared to its average volume of 1,316,170. The company has a market cap of $15.96 billion, a P/E ratio of 12.50, a P/E/G ratio of 7.22 and a beta of 0.93. The business has a 50-day moving average of $22.22 and a two-hundred day moving average of $21.28. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $27.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.